Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment

Sanna-Kaisa Herukka; Anja Hviid Simonsen; Niels Andreasen; Ines Baldeiras; Maria Bjerke; Kaj Blennow; Sebastiaan Engelborghs; Giovanni B Frisoni; Tomasz Gabryelewicz; Samantha Galluzzi; Ron Handels; Milica G Kramberger; Agnieszka Kulczyńska; Jose Luis Molinuevo; Barbara Mroczko; Agneta Nordberg; Catarina Resende Oliveira; Markus Otto; Juha O Rinne; Uroš Rot; Esen Saka; Hilkka Soininen; Hanne Struyfs; Silvia Suardi; Pieter Jelle Visser; Bengt Winblad; Henrik Zetterberg; Gunhild Waldemar

doi:10.1016/j.jalz.2016.09.009

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment

Sanna-Kaisa Herukka, Anja Hviid Simonsen, Niels Andreasen, Ines Baldeiras, Maria Bjerke, Kaj Blennow, Sebastiaan Engelborghs, Giovanni B Frisoni, Tomasz Gabryelewicz, Samantha Galluzzi, Ron Handels, Milica G Kramberger, Agnieszka Kulczyńska, Jose Luis Molinuevo, Barbara Mroczko, Agneta Nordberg, Catarina Resende Oliveira, Markus Otto, Juha O Rinne, Uroš RotEsen Saka, Hilkka Soininen, Hanne Struyfs, Silvia Suardi, Pieter Jelle Visser, Bengt Winblad, Henrik Zetterberg, Gunhild Waldemar

Institut for Klinisk Medicin

67 Citationer (Scopus)

90 Downloads (Pure)

Abstract

This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with mild cognitive impairment (MCI). The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost-effectiveness, 3) interpretation of results, and 4) patient counseling. The working group recommended using CSF AD biomarkers in the diagnostic workup of MCI patients, after prebiomarker counseling, as an add-on to clinical evaluation to predict functional decline or conversion to AD dementia and to guide disease management. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre- and post-biomarker counseling.

Originalsprog	Engelsk
Tidsskrift	Alzheimer's & Dementia
Vol/bind	13
Udgave nummer	3
Sider (fra-til)	285-295
Antal sider	11
ISSN	1552-5260
DOI	https://doi.org/10.1016/j.jalz.2016.09.009
Status	Udgivet - 1 mar. 2017

Adgang til dokumentet

10.1016/j.jalz.2016.09.009Licens: CC BY-NC-ND

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairmentForlagets udgivne version, 852 KBLicens: CC BY-NC-ND

Citationsformater

Herukka, S.-K., Simonsen, A. H., Andreasen, N., Baldeiras, I., Bjerke, M., Blennow, K., Engelborghs, S., Frisoni, G. B., Gabryelewicz, T., Galluzzi, S., Handels, R., Kramberger, M. G., Kulczyńska, A., Molinuevo, J. L., Mroczko, B., Nordberg, A., Oliveira, C. R., Otto, M., Rinne, J. O., ... Waldemar, G. (2017). Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's & Dementia, 13(3), 285-295. https://doi.org/10.1016/j.jalz.2016.09.009

Herukka, S-K, Simonsen, AH, Andreasen, N, Baldeiras, I, Bjerke, M, Blennow, K, Engelborghs, S, Frisoni, GB, Gabryelewicz, T, Galluzzi, S, Handels, R, Kramberger, MG, Kulczyńska, A, Molinuevo, JL, Mroczko, B, Nordberg, A, Oliveira, CR, Otto, M, Rinne, JO, Rot, U, Saka, E, Soininen, H, Struyfs, H, Suardi, S, Visser, PJ, Winblad, B, Zetterberg, H & Waldemar, G 2017, 'Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment', Alzheimer's & Dementia, bind 13, nr. 3, s. 285-295. https://doi.org/10.1016/j.jalz.2016.09.009

@article{bbd3f8f508eb4853b534d2cb9b02fb25,

title = "Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment",

abstract = "This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with mild cognitive impairment (MCI). The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost-effectiveness, 3) interpretation of results, and 4) patient counseling. The working group recommended using CSF AD biomarkers in the diagnostic workup of MCI patients, after prebiomarker counseling, as an add-on to clinical evaluation to predict functional decline or conversion to AD dementia and to guide disease management. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre- and post-biomarker counseling.",

keywords = "Alzheimer Disease, Amyloid beta-Peptides, Biomarkers, Cognitive Dysfunction, Humans, MEDLINE, Peptide Fragments, tau Proteins, Journal Article, Review",

author = "Sanna-Kaisa Herukka and Simonsen, {Anja Hviid} and Niels Andreasen and Ines Baldeiras and Maria Bjerke and Kaj Blennow and Sebastiaan Engelborghs and Frisoni, {Giovanni B} and Tomasz Gabryelewicz and Samantha Galluzzi and Ron Handels and Kramberger, {Milica G} and Agnieszka Kulczy{\'n}ska and Molinuevo, {Jose Luis} and Barbara Mroczko and Agneta Nordberg and Oliveira, {Catarina Resende} and Markus Otto and Rinne, {Juha O} and Uro{\v s} Rot and Esen Saka and Hilkka Soininen and Hanne Struyfs and Silvia Suardi and Visser, {Pieter Jelle} and Bengt Winblad and Henrik Zetterberg and Gunhild Waldemar",

year = "2017",

month = mar,

day = "1",

doi = "10.1016/j.jalz.2016.09.009",

language = "English",

volume = "13",

pages = "285--295",

journal = "Alzheimer's & Dementia",

issn = "1552-5260",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment

AU - Herukka, Sanna-Kaisa

AU - Simonsen, Anja Hviid

AU - Andreasen, Niels

AU - Baldeiras, Ines

AU - Bjerke, Maria

AU - Blennow, Kaj

AU - Engelborghs, Sebastiaan

AU - Frisoni, Giovanni B

AU - Gabryelewicz, Tomasz

AU - Galluzzi, Samantha

AU - Handels, Ron

AU - Kramberger, Milica G

AU - Kulczyńska, Agnieszka

AU - Molinuevo, Jose Luis

AU - Mroczko, Barbara

AU - Nordberg, Agneta

AU - Oliveira, Catarina Resende

AU - Otto, Markus

AU - Rinne, Juha O

AU - Rot, Uroš

AU - Saka, Esen

AU - Soininen, Hilkka

AU - Struyfs, Hanne

AU - Suardi, Silvia

AU - Visser, Pieter Jelle

AU - Winblad, Bengt

AU - Zetterberg, Henrik

AU - Waldemar, Gunhild

PY - 2017/3/1

Y1 - 2017/3/1

N2 - This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with mild cognitive impairment (MCI). The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost-effectiveness, 3) interpretation of results, and 4) patient counseling. The working group recommended using CSF AD biomarkers in the diagnostic workup of MCI patients, after prebiomarker counseling, as an add-on to clinical evaluation to predict functional decline or conversion to AD dementia and to guide disease management. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre- and post-biomarker counseling.

AB - This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-β1-42, tau, and phosphorylated tau in the diagnostic evaluation of patients with mild cognitive impairment (MCI). The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost-effectiveness, 3) interpretation of results, and 4) patient counseling. The working group recommended using CSF AD biomarkers in the diagnostic workup of MCI patients, after prebiomarker counseling, as an add-on to clinical evaluation to predict functional decline or conversion to AD dementia and to guide disease management. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre- and post-biomarker counseling.

KW - Alzheimer Disease

KW - Amyloid beta-Peptides

KW - Biomarkers

KW - Cognitive Dysfunction

KW - Humans

KW - MEDLINE

KW - Peptide Fragments

KW - tau Proteins

KW - Journal Article

KW - Review

U2 - 10.1016/j.jalz.2016.09.009

DO - 10.1016/j.jalz.2016.09.009

M3 - Journal article

C2 - 28341066

SN - 1552-5260

VL - 13

SP - 285

EP - 295

JO - Alzheimer's & Dementia

JF - Alzheimer's & Dementia

IS - 3

ER -

Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater